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Introduction
Cervical cancer is the fourth leading cause of  cancer incidence and mortality in women worldwide (1). In 
2021, a total of  14,480 new cervical cancer diagnoses and 4290 cervical cancer deaths are expected in the 
United States alone (2). Persistent HPV infection is causative for more than 91% of  cervical cancer cases 
(3).Encoded within the HPV genome are 2 oncogenes that target key cell regulatory components. HPV 
E6 targets p53, and HPV E7 targets pRb and p130, which are integral components of  the pRb-related 
transcriptional repressor DREAM complex (4–7). Through E6 and E7, the virus induces cell immortal-
ization resulting in a hyperproliferative state that facilitates viral replication. High-risk HPV genotypes use 
alternative splicing to switch between transcription of  HPV E6 to E7 (8). Although a few of  the high-risk 
HPV genotypes are able to encode multiple E6 splice variants, all of  the high-risk HPV genotypes encode 
the E6*I (hereinafter referred to as E6*) splice variant (9). This primary alternatively spliced variant uses 
the first 5′ alternative splice site in the E6 open reading frame to generate a truncated E6 splice variant, 
E6*, and the full-length E7 transcript (8). E6* has been previously reported to encode a functional protein 
that acts as an antagonist to full-length HPV E6 (10, 11). HPV infection itself, however, is not sufficient to 
induce cervical cancer (12). The hyperproliferative state associated with E6 and E7 expression results in 
the development of  cervical interepithelial neoplasms (CIN) 1–3, which can spontaneously regress. Over 
time, if  HPV infection persists, the uncontrolled replication of  the infected cell leads to the accumulation 
of  mutations that can further deregulate and reprogram the cell, leading to tumorigenesis.
Previous studies have demonstrated that HPV status and HPV genotype are both prognostic indi-
cators in cervical cancer patients (13–18). Cervical cancer patients with undetectable levels of  HPV in 
their tumors have poor progression-free survival (PFS) and overall survival (OS) outcomes compared 
with patients with HPV+ tumors (13, 14). However, this HPV+ survival benefit is not binary, and patients 
with HPV genotypes other than HPV 16 in their tumors have worse PFS and OS after treatment than 
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patients with HPV 16 detected (HPV16+) tumors (15–18). This observation is also seen when HPV gen-
otypes are grouped by viral clade, where patients with α7 clade–positive tumors, which includes HPV 
18, have worse PFS and OS compared with patients with α9-positive tumors, which includes the HPV 
16 genotype (16, 18). Since HPV status has been shown to correlate with patient outcomes, it could be 
used as a diagnostic biomarker to identify patients who are likely to fail the current standard-of-care 
treatment strategy. However, the molecular basis of  non–HPV 16 genotypes (HPVOther) conferring worse 
prognosis is not well understood. Additionally, even within previously reported studies, the HPV 16 
patient subsets have PFS and OS below 75%, indicating that — within this clinically benefiting group 
— there may be some patients who are likely to fail their standard-of-care treatment and would bene-
fit from a more personalized treatment plan (15, 17). Therefore, identifying a viral diagnostic marker 
independent of  HPV genotype may be beneficial. Currently, it is unknown whether expression of  HPV 
alternative transcripts affects tumor response to chemoradiation. The primary purpose of  this study was 
to investigate whether variation in the viral transcriptome between HPV16+ and HPVOther cervical cancer 
tumors correlated with poor prognosis after standard-of-care chemoradiation treatment (CRT). A sec-
ondary goal was to determine how HPV transcript expression, including the expression of  alternatively 
spliced forms of  HPV E6, affects cellular response to standard-of-care CRT.
Results
HPV genotypes detected in cohort. In our 88-patient cohort, 87.5% of  patients had detectable HPV DNA, and 
patients with undetectable HPV DNA were excluded from the study. Patients with HPVOther genotypes 
or multiple HPV genotypes detected were grouped together as HPVOther. Forty-eight patients had HPV16+ 
tumors, and 29 were HPVOther: 9 HPV-18, 4 HPV-33, 3 HPV-45, 3 HPV-52, 3 HPV-59, 1 HPV-31, 1 HPV-56, 
1 HPV-58, 1-HPV 68a, 1 HPV-82, and 2 patients with multiple HPV genotypes detected (Table 1). Initial 
analysis focused on confirming whether prognostic differences based upon HPV genotype, clade, and viral 
integration observed in our institutional cohort was consistent with previously published studies. Patients 
with HPV16+ tumors had better PFS (P = 0.049) and OS (P = 0.004) compared with HPVOther patients (Fig-
ure 1). Similarly, patients with α9-positive tumors (n = 57) had better PFS (P = 0.012) and OS (P = 0.084) 
compared with those with α7 clade (n =16) (Supplemental Figure 1, A and B; supplemental material avail-
able online with this article; https://doi.org/10.1172/jci.insight.138734DS1). Viral integration state was 
assessed using RNA sequencing (RNAseq) analysis, and integration events occurred in 70.3% of  HPV16+ 
and 85.7% of  HPVOther tumors (Supplemental Figure 1E). Patients with integrated HPV had less favorable 
PFS (P = 0.067) and OS (P = 0.057) compared with patients with episomal HPV, although these results 
were not statistically significant (Supplemental Figure 1, C and D).
There were no significant differences in patient age at time of  diagnosis, tumor staging, lymph node 
involvement, and metastasis at the time of  diagnosis between HPV16+ and HPVOther genotype patient groups 
(Table 2). Additionally, both patient groups had comparable radiation treatment intent and treatment 
completion (Table 2). Despite there being no difference in clinical characteristics or treatment strategies, 
patients with HPV16+ tumors had more favorable outcomes after chemoradiation compared with patients in 
the HPVOther group. Patients with HPVOther cervix tumors experienced more disease recurrence (P = 0.032) 
and increased mortality (P = 0.018) after CRT (Table 2).
Comparison of  viral transcription efficiency between HPV 16 and HPV other genotypes. RNA from 68 patient 
biopsies was isolated, and whole transcriptome sequencing, including all host and viral transcripts, was 
performed. Viral expression of  E6, E6*, and E7 was quantified and compared between HPV16+ (n = 36) and 
HPVOther (n = 17) patient groups. The HPV E6* and E7 transcripts were more highly expressed than HPV 
E6 in both HPV16+ and HPVOther groups (Figure 2A). HPVOther tumors had an average of  2.9-fold increase in 
HPV E6 (P = 0.0085) and 2.0-fold increase in E6* (P = 0.025) transcript expression compared with HPV16+ 
tumors. There was an average 1.5-fold increase in HPV E7 transcript expression of  HPVOther compared with 
HPV16+ tumors; however, this was not statistically significant (Figure 2A).
Similar observations were seen when HPV transcript expression was compared between integrated (n = 
44) and episomal HPV (n = 14) patient groups (Supplemental Figure 1F).
We used publicly available TCGA cervical cancer data as a validation cohort for HPV transcript expres-
sion (https://portal.gdc.cancer.gov/). Similar to our cohort, 56% of  tumor samples were HPV16+ and 43% 
were HPVOther in the cervix TCGA cohort (Supplemental Figure 2A). There was no significant difference 
in the viral integration state between the HPV genotype groups (Supplemental Figure 2B). The HPVOther 
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patient group had an average fold increase of  3.0 for HPV E6 (P = 8.1 × 10–12), 2.2 for E6* (P = 2.4 × 10–9), 
and 1.4 for E7 (P = 0.0012) (Supplemental Figure 2C).
The relative expression levels of  HPV viral transcripts were tested as predictive biomarkers for 
CRT outcome using prospectively collected clinical outcome data from our study’s uniformly treated 
patient cohort. HPV E6, E6*, and E7 transcript expression levels were grouped as high (reads per 
kilobase of  transcript per million mapped reads [RPKM] > upper quartile) and low (RPKM < upper 
quartile). High HPV E6* expression was a poor prognostic indicator for PFS (P = 0.047) and OS (P 
= 0.033) after CRT (Figure 2, B and C). Interestingly, expression of  HPV E6 or E7 alone was insuffi-
cient to significantly stratify patient survival outcomes (Supplemental Figure 3). To determine whether 
increased expression of  HPV E6* could be used as an independent prognostic biomarker, we also 
analyzed the HPV16+ subset of  patients alone (n = 36). HPV16+ patients with high HPV E6* expression 
again exhibited worse PFS (P = 0.38) and OS (P = 0.33) (Figure 2, D and E), although this did not 
reach the level of  statistical significance.
HPV transcript expression correlates in vitro with radiotherapy (RT) sensitivity. To test our hypothesis in vitro, 
cervical cancer cell lines CaSki, SiHa, and SW756 were evaluated for their relative transcript expression 
of  HPV E6, E6*, and E7 by quantitative PCR (qPCR). CaSki (HPV 16) had higher levels of  E6, E6*, and 
E7 transcript expression compared with SiHa (HPV 16) and SW756 (HPV 18) cells (Supplemental Figure 
4A). Next, we determined the sensitivity to radiation in these cervical cancer lines. The CaSki cell line with 
high viral transcript levels was more resistant to increasing doses of  radiation compared with SiHa (4 Gy, P 
= 0.032) and SW756 (4 Gy, P = 0.017) cell lines with low transcript levels (Supplemental Figure 4B). 
Taken together, these results suggest that high viral transcript expression correlates with resistance to radi-
ation in cervical cancer cells, consistent with our clinical observations.
Next, we wanted to remove any potentially confounding effects of  HPV genotype and test whether alter-
ations to HPV viral transcript expressions alone could induce resistance to CRT. The low HPV transcript 
expressing SiHa cell line was selected to evaluate the effect of  increased E6 and E6* expression on cell sensi-
tivity to CRT. HPV 16 E6 and E6* protein coding sequences were ligated into pCMV-6 mammalian expres-
sion vectors and transfected in SiHa cells, and primers specific to the vector HPV 16 E6 and E6* sequences 
were used to quantify vector specific transcript expression by qPCR (Supplemental Figure 5, A and B). E6 
overexpression in SiHa cells resulted in a 26% reduction in baseline p53 levels, as expected (P = 0.0107). E6* 
overexpression in SiHa cells increased p53 protein expression compared with WT SiHa (fold change [FC] = 
1.35, P = 0.0107) (Figure 3, A and B), consistent with previously published findings that E6* is an antagonist 
of  E6-mediated p53 degradation (10).
Table 1. HPV genotypes
HPV genotype (n = 88)
HPV 16 48
HPV 18 8











> 10 HPV types 2
HPV 16 + others 1
HPV 18 + others 1
HPV-negative 11
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E6 and E6* expression affects cellular response to CRT. We assessed the effect of  E6 and E6* overexpres-
sion in SiHa cells on survival following CRT. Both, E6* and E6 overexpression decreased cell sensitivity 
to increasing doses of  radiation treatment (Figure 3, C and D). Increased expression of  E6* or E6 did 
not affect cell cycle progression following CRT (Supplemental Figure 6, A–F). We found that apoptosis 
was not the primary mechanism of  cell death in the cervical cancer lines following CRT, although all cell 
lines were able to induce apoptotic cell death following etoposide treatment (Supplemental Figure 6, G–J). 
Figure 1. HPV genotype 
significantly stratifies 
patient outcomes. (A and B) 
Progression-free and overall 
survival curves stratified by 
HPV genotype (pink, HPV 16; 
brown, HPV other; gray, HPV 
undetected). Log-rank test 
was used to determine statis-
tical significance, calculated 
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Kinetics of  DNA damage induction and repair were determined by monitoring the formation and resolu-
tion of  γH2AX foci after radiation. WT, as well as E6 and E6* overexpressing SiHa cells, showed similar 
levels of  γH2AX foci 10 minutes after exposure to radiation. Twenty-four hours following irradiation, 
γH2AX were resolved in E6 expressing SiHa cells (P = 0.017), whereas WT cells and cells expressing E6* 
had residual γH2AX foci suggestive of  unrepaired DNA breaks in the latter 2 lines (Figure 3, E and F).
E6* overexpression induces p21-mediated cellular senescence. To test whether the function of  p53 as a transcrip-
tion factor is affected by viral transcript expression, qPCR was performed for 6 p53 target genes. The SiHa 
E6* overexpressing cell line had higher CDKN1A (P = 0.021) and NOXA (P = 0.0089) transcript expression, 
and the SiHa E6 overexpressing cell line had lower PUMA (P = 0.045) transcript expression compared with 
the WT SiHa cell line (Figure 4A and Supplemental Figure 5, C and D). BAX, GADD45A, and MDM2 tran-
script expression was not affected by either E6 or E6* overexpression (Supplemental Figure 5, E–G). CDK-
N1A encodes the p21 protein, which is a direct target of  p53 regulation. SiHa E6* cells had 3.9-fold higher p21 
protein expression compared with WT SiHa (P = 0.0028) (Figure 3A). The functionality of  p21 was assessed 
in the 3 cell lines, including cellular proliferation and induction of  cellular senescence. The p53 and p21 low 
SiHa E6 cell line had the fastest rate of  proliferation, followed by WT SiHa. SiHa E6* overexpressing had the 
lowest proliferation rate (Figure 4B). High p53 and p21 expression can induce cellular senescence (19–21). To 
test whether increased p21 was associated with increased senescence in E6* expressing cervical cancer, SiHa 
(parent), SiHa E6*, and SiHa E6 overexpressing cells were plated and grown for 8 days and then stained for 
senescence-associated β-galactosidease (SA-β-gal) expression, and senescent cells were quantified. SiHa cells 
overexpressing E6* had more SA-β-gal+ cells compared with WT SiHa (P = 0.029) and SiHa E6 cell lines 
Table 2. Patient baseline characteristics
HPV 16 (n = 48) HPV other (n = 29) P value
Age at diagnosis (median, range) 51.5 (25–79) 53 (38–85) P = 0.235
Stage P = 0.468
 Ib1 8 5
 Ib2 9 1
 IIa 0 1
 IIb 15 11
 IIIa 2 1
 IIIb 12 9
 IVa 1 0
 IVb 1 1
Lymph nodes at diagnosis 24 15 P = 0.873
 Aortic 3 3
 Pelvic 19 10
 SCV 2 2
Metastasis 2 1 P = 1
 Bone 1 0
 Lung 1 1
Radiation treatment intent P = 0.371
 Curative 45 25
 Palliative 3 3
 None 0 1
Completed treatment 46 26 P = 0.29
 Recurrence 16 18 P = 0.015
  Pelvic 4 10
  Distant 8 5
  Both 3 3
  No data 1 0
 Overall survival P = 0.035
  Alive 32 12
  Dead 16 17
Wilcoxon’s signed-rank test used for age. Fisher exact test used for all other characteristics
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Figure 2. HPV E6, E6*I, and E7 transcript expression in 
Washington University in St. Louis School of Medicine 
(WUSM) cohort. (A) Comparison of HPV transcript expres-
sion between HPV 16 (pink) and non–HPV 16 + (brown) 
patient tumors (*P < 0.05, **P < 0.01; nonparametric 
Wilcoxon’s signed-rank test). (B–E) The full WUSM cohort 
(B and C) and the HPV 16 + patient subset (D and E) were 
stratified based upon their relative HPV E6*I transcript 
expression, where high > Q3 and low < Q3, and assessed 
for progression-free (B and D) and overall survival (C and E). 
Significance calculated by log rank test using the survminer 
package in R version 3.5.2.
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(P = 0.057) (Figure 4, C and D). There was no difference in SA-β-gal positivity between SiHa E6 and WT 
SiHa cells (P = 0.2). Increase in p21 is known to induce G1 cell cycle arrest (22); however, neither E6* or E6 
overexpression induced a G1 arrest (Supplemental Figure 5, H and I). Additionally, previous reports have 
implied that an increase in p21 levels leads to transcriptional repression of  cell cycle genes due to an inter-
action with the RB and DREAM complex (23). To test this, 5 DREAM target genes were selected, and 
their expression was evaluated across the cell lines; however, no significant alteration was found except for a 
decrease in KIF23, which was observed in both cell lines expressing p21 high, E6*, and p21 low, E6 (P = 0.01) 
(Supplemental Figure 5J). Both the parental SiHa cell line and the engineered SiHa E6* and SiHa E6 cell lines 
Figure 3. E6* and E6 over-
expression effect on CRT 
response. (A) SiHa E6 and 
E6* expressing cell lines were 
quantified for p53 and p21 
protein expression by Western 
blot. Representative blots; 
lanes run on the same gel but 
were not contiguous. Protein 
analysis was independently 
replicated 3 times. (B) Band 
quantification of p53 protein 
expression was performed on 3 
independent blots (*P < 0.05, 
Wilcoxon’s signed-rank test). (C 
and D) Clonogenic survival was 
assessed by colony formation 
assay. (C) Representative 
images of colony formation 
assay shown. (D) Normalized 
surviving fraction of SiHa 
parental (black) versus SiHa 
E6* (blue) and SiHa E6 (brown) 
mean ± SEM. (C and D) Repre-
sentative experiment shown 
with technical replicates n = 
3 for each condition, one-way 
ANOVA test used. Experiment 
independently repeated 3 
times). (E and F) DNA damage 
response was quantified using 
γH2AX p-S139 foci–positive 
cells. (E) Representative imag-
es of γH2AX foci (green) and 
nuclei stained by DAPI (blue) 
immunofluorescence of SiHa 
parental, SiHa E6*, and SiHa 
E6 cell lines. (F) Quantification 
of γH2AX foci–positive cells 
(>3 foci/nuclei) at 10 minutes, 
2 hours, 6 hours, 12 hours, and 
24 hours after 2Gy radiation 
treatment. Each condition had 
4–10 random images quanti-
fied; data are representative 
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have HPV E7 expression intact, and E7 expression has been previously reported to abrogate both p21-depen-
dent G1 cell cycle arrest and the p53–p21/DREAM pathway (24, 25).
p21 knockdown sufficient to sensitize SiHa E6* to radiation treatment. Lastly, we tested whether knockdown 
of  p21 is sufficient to rescue treatment sensitivity in the p21 high E6* overexpressing cell line (Supplemen-
tal Figure 5, K and L). Transient knockdown of  p21 in the parental SiHa and E6 overexpressing cell lines, 
which are low in p21 expression, did not have a significant impact on sensitivity to radiation treatment. 
Figure 4. HPV E6* and E6 overexpression stabilizes p53 and p21 stabilization, leading to induction of cellular senescence. (A) CDKN1A (p21) expression 
was quantified using qPCR (normalized to GAPDH and ACTB transcript expression) (n = 6 biological replicates used for each, Student’s t test). (B) Prolif-
eration assay of SiHa parental (black) versus SiHa E6* (blue) versus SiHa E6 (brown). Data representative from 3 independent experiments, mean ± SEM, 
1-way ANOVA. (C and D) Representative images of SA-β-gal staining (arrow, SA-β-gal+) and quantification of SA-β-gal+ cells. Representative experiment 
shown from 25 random field images obtained per sample. Wilcoxon’s signed-rank test. *P < 0.05, **P < 0.01. Experiment was independently replicated 2 
times.) (E) Normalized surviving fraction of each SiHa cell line treated with control siRNA versus a p21 targeting siRNA mean ± SEM. Representative exper-
iment shown with technical replicates n = 3 for each condition. Student’s t test used. Experiment independently repeated 3 times.
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In the p21 high E6* overexpressing cell line, transient knockdown of  p21 led to an increase in cell sensitiv-
ity to increasing doses of  radiation treatment (Figure 4E). Altogether, these findings indicate that overex-
pression of  the p53 agonist E6* stabilizes p53 expression, leading to upregulation of  p21 and subsequent 
induction of  cellular senescence, and overall reduced sensitivity to CRT. This phenotype can be rescued by 
knockdown of  p21 prior to radiation treatment.
Discussion
Treatment for cervical cancer is currently guided by clinical staging, which includes the results of  
physical examination and whole-body imaging. In general, early-stage cervical cancers are managed 
by surgical resection, while locally advanced cases are treated with pelvic irradiation and the concur-
rent administration of  cisplatin chemotherapy. While this treatment strategy is effective, 30%–50% of  
patients with locally advanced cervical cancer will fail CRT, necessitating the need to develop predictive 
biomarkers to assist in treatment planning. Current clinical guidelines do not require HPV testing of  
newly diagnosed cervical cancer. In this study, we demonstrate that expression of  an HPV genotype 
other than HPV 16 is a predictive biomarker for a poor disease response to the standard-of-care CRT 
using a population of  patients who were uniformly treated with standard-of-care CRT with prospective-
ly collected clinical outcomes. Furthermore, using RNAseq, we demonstrated that cervical tumors with 
HPVOther genotypes had higher viral transcript expression of  HPV E6 and E6*. High HPV E6* expres-
sion was significantly associated with patient risk of  developing disease recurrence and was a predictive 
biomarker of  poor disease response following CRT. Interestingly, the prognostic value of  high HPV E6* 
expression was also observed when restricting analysis to the HPV 16 patient subset, indicating that it 
may be a valuable genotype-independent predictive biomarker. These results suggest that more detailed 
analysis of  HPV genotype and HPV-related gene expression could be used to identify cervical cancer 
patients at risk for treatment failure from standard-of-care chemoradiation.
These survival differences affected by the HPV types are not exclusive to cervical cancer. Approximate-
ly 20% of  oropharyngeal squamous cell cancer (OPSCCs) are HPV related, and patients with HPV-related 
OPSCC have favorable outcomes after chemoradiation (26, 27). More recently, HPV genotype differences 
are being appreciated in HPV+ head and neck squamous cell carcinoma (HNSCC) where HPV 18 genotype 
has been identified as an independent poor prognostic factor of  OS (28). In addition, expression of  alterna-
tive transcripts such as HPV E1–E4 has been identified as a candidate biomarker for treatment resistance 
in HPV+ head and neck cancer (28). Based upon the results found in our study with prospectively collected 
tumor specimens and patient outcomes, as well as other previous studies, HPV genotype should be consid-
ered a predictive biomarker for outcome after chemoradiation. Furthermore, the association between HPV 
genotype and the expression of  HPV-related genes, including full-length E6 and the alternatively spliced 
variant E6*, merit further study.
In this study, we focused on interrogating the relationship between HPV genotypes and viral transcript lev-
els. Additionally, previous studies have shown that integrated HPV is a poor prognostic indicator in cervical can-
cer patients, although the biological mechanism to explain this clinical observation is poorly understood (29, 30). 
In our institutional cohort, 77% of HPV16+ patients had viral integration, whereas 83% of patients with HPVOther 
tumors had viral integration (Supplemental Figure 1A). Similarly, in the cervix TCGA cohort, 70% of HPV16+ 
patient tumors had viral integration compared with 86% of HPVOther tumors (Supplemental Figure 2A). For 
both independent patient cohorts, HPVOther tumors tended to have a higher incidence of viral integration com-
pared with patients with HPV16+ tumors. Additionally, in our institutional cohort, patients with HPV integrated 
tumors had worse PFS (P = 0.067) and OS (P = 0.057) after CRT; however, perhaps due to the small cohort 
size, these survival differences did not meet the threshold for significance (Supplemental Figure 1, B and C). 
Factors regulating HPV integration into the host genome are poorly understood. Host genome sites where HPV 
integration frequently occurs have been reported throughout the genome and are found within fragile sequence 
sites and areas of open chromatin (31). HPV integration into the host genome can result in transcription of viral-
host fusion proteins and influence transcriptional activity of neighboring host genes via a pseudo-promoter effect 
(32). Using both our institutional cohort and validating with the cervix TCGA cohort, we found that the viral 
integration state also correlated with HPV transcript expression (Supplemental Figure 1D and Supplemental 
Figure 2D). As previously mentioned, for both our institutional and TCGA cervix cohorts, HPVOther tumors 
had a higher incidence of viral integration, and the episomal group is primarily composed of patients with 
HPV16+ tumors (Supplemental Figure 1A and Supplemental Figure 2B). Taken together, this raises the question 
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as to whether HPVOther genotypes are more efficient in integrating their viral genome into the host genome, and 
perhaps this is why these patient tumors have higher viral transcript efficiency; however, additional in vitro work 
will need to be done to determine the relationship between HPV genotype, viral state and transcript expression.
In vitro characterization of  high HPV E6* and E6 transcript expression revealed that increasing expres-
sion of  either transcript was sufficient to induce CRT resistance. Each transcript induced treatment resis-
tance through different mechanisms, but both involved differences in E6-related regulation of  p53 and 
downstream p21 activation. Increasing full-length E6 expression inhibited p53 and p21 activity, resulting in 
enhanced efficiency of  DNA repair of  RT-induced lesions as evidenced by Figure 3, E and F. In contrast, 
high E6* expression inhibited E6-induced degradation of  p53, resulting in p53 stabilization and down-
stream p21 activation, leading to induction of  cellular senescence as shown in Figure 3A and Figure 4, C 
and D. Furthermore, we demonstrated that the decrease in treatment sensitivity observed in the high E6* 
expression cell line was dependent on the increase in p21 expression and could be sensitized to treatment 
following p21 knockdown (Figure 4E). Work is ongoing in our lab to use this model in vivo and investigate 
the pairing of  novel drug therapies to sensitize high viral transcript expressing tumors to CRT.
Cellular senescence is a state in which cells no longer proliferate but are still viable. These cells alter the 
tumor microenvironment because of  their senescence-associated secretory profile (SASP) and can repro-
gram cells of  the microenvironment to a tumor-favorable phenotype (33). Senescent cells are nonprolifera-
tive and, therefore, have an intrinsic resistance to radiation treatment. However, an emerging group of  che-
motherapies are being developed to target and kill senescent cells (34). This new chemotherapy class should 
be tested for its efficacy in treating E6* overexpressing HPV transformed cell lines to determine whether 
targeting senescent cells will lead to better treatment efficacy following CRT (35, 36).
The enhanced DNA damage repair we observed in high E6 expressing cells should be further inves-
tigated to determine the mechanism of  repair being affected by HPV E6 expression. In Figure 3, E and 
F, we show that HPV E6 overexpressing cells had enhanced phosphorylated-γH2AX foci clearance after 
radiation treatment compared with WT and E6* overexpressing cells. HPV E6 targets p53 for degrada-
tion, and — as we show in Figure 3A and Figure 4A — this decrease in p53 degradation coincides with a 
decrease in p21 transcript and protein expression. One of  the functions of  p21 is to inhibit PCNA, which is 
an essential component of  DNA damage repair (37, 38). HPV E7 has been previously shown to upregulate 
PCNA expression (39). In our in vitro system, the SiHa E6 overexpressing cells express endogenous HPV 
16 E7; therefore, the enhanced DNA repair that we find in this cell line following radiation treatment may 
be due to the synergy between inhibition of  p21 by HPV E6 and the upregulation of  PCNA by HPV E7. 
However, future studies will be required to identify the DNA damage repair pathway being affected by this 
alteration. Patients with high E6 expression could benefit from pairing radiation treatment with a DNA 
damage response inhibitor targeting the pathway affected by E6 overexpression.
In conclusion, using a population of  patients uniformly treated with standard-of-care CRT with pro-
spectively collected clinical outcome data, this study confirms HPV genotype and identifies, for the first 
time to our knowledge, HPV transcriptional efficiency as predictive biomarkers of  poor patient outcomes 
after standard-of-care chemoradiation in cervical cancer. We validated the association between HPV gen-
otype and viral transcript expression efficiency using the cervix TCGA cohort, which also demonstrated 
that HPV 16 + tumors indeed have lower transcriptional efficiency of  HPV E6, E6*, and E7. Using cervical 
cancer cell lines engineered to overexpress E6 and E6* from HPV 16, we demonstrate that transcript vari-
ants of  HPV E6 are associated with treatment resistance to standard-of-care CRT. While overexpression of  
full-length HPV E6 is associated with enhanced DNA repair, overexpression of  HPV E6* is associated with 
tumor cell senescence. These results support more detailed examination of  HPV genotype and viral tran-
script expression in patients with locally advanced cervical cancer and suggest that this information may 
be used in the future to identify patients at risk of  CRT failure. In addition, these results provide important 
insights into treatment resistance mechanisms for HPV+ tumors.
Methods
Patients. Patient tumor biopsies and blood were obtained prior to the initiation of therapy and stored at the 
Tissue Procurement Facility at Washington University in St. Louis School of Medicine. RT consisted of exter-
nal beam irradiation and intracavitary brachytherapy, per institutional guidelines (Washington University in 
St. Louis School of Medicine), and concurrent cisplatin or carboplatin chemotherapy was also administered. 
Median follow-up time for patients alive at the time of last follow-up was 62 months (range, 25–92 months). 
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Inclusion in downstream data analysis required detectable HPV in patient tumors. In the reporting of this data, 
we have adhered to REMARK guidelines (40).
Clinical follow-up. Patients were followed at the following time points after the completion of  CRT: 6 
weeks, 3 months, 6 months, 12 months, 18 months, 2 years, 3 years and 5 years. Physical examination includ-
ing a pelvic exam was performed at each visit. Patients received posttreatment 18F-Flouro-deoxy-glucose 
positron emission tomography (FDG-PET) scans at 3 months after therapy to assess treatment response.
HPV genotyping. DNA isolated from 88 pretreatment tumors were sequenced using next-generation 
sequencing, and probes for the following HPV genotypes were used to identify the HPV genotypes present 
within the tumor: high-risk HPV-16, -18, -31, -33-, 35, -39, -45, -51, -52 -56, -58, and -59 genotypes and 
low-risk HPV-6b, -11, -26, -30, -53, -54, -57, -61, -66, -68a, -70, -72, -73, -82, -98, -99, -100, -104, -105, and 
-113. SAMtools idxstats (41) was used to extract the number of  reads mapping to each HPV accession, and 
HPV positivity was defined as any sample with at least 100 HPV reads detected for one of  the 32 genotypes. 
Patient groups were defined as patients with HPV16+, HPVOther, or no HPV detected in the sample (HPV 
undetected). Patients with undetectable HPV were excluded from study analysis.
Viral transcriptome and integration state. RNA was extracted, with 68 patients yielding at least the 0.5 μg of  
RNA with RIN > 7 sufficient for library preparation. RNAseq was performed for these patient samples using 
the Illumina HiSeq 3000. Raw sequencing reads were aligned to reference human and HPV viral genomes 
in GRCh38.d1.vd1 using STAR 2.7.0f, with chimSegmentMin set to 18 (42). STAR-generated chimeric 
junction files were parsed for reads that were chimeric between human and HPV references, and the cor-
responding alignment information and nucleotide sequences were extracted and manually inspected using 
BLAT and BLAST to verify viral integration. To obtain read counts for HPV E6, E6*, and E7, sequences 
were aligned against HPV reference genomes for both the E6 and E6* alternative splice using BWA 0.7.17-
r1188. Numbers of  junction spanning reads for WT E6 (NE6,J) and E6* (NE6*,J) were counted, as well as the 
number of  reads aligned to E6 between the splice sites (NE6,b). The remaining Na reads align to the ranges over 
which E6 and E6* are identical. Total counts of  E6 (NE6) and E6* (NE6*) reads were, therefore, obtained by 
assigning these reads to WT or E6* transcripts based on the proportions of  each type of  junction spanning 
read normalized by the size of  the nt ranges from which such a read could arise, as in the following formulas:
Counts of  reads aligned to HPV E6, E6*, and E7 were then normalized by RPKM.
TCGA viral transcriptome and integration state. Viral gene expression and integration status was obtained for 
304 TCGA-CESC primary tumor samples using a similar method to that employed for our institutional data. 
RNAseq reads were extracted and aligned to reference human and HPV viral genomes in GRCh38.d1.vd1 using 
STAR 2.7.0f with chimSegmentMin set to 18. Reads that were chimeric between human and HPV references 
were extracted, and samples with greater than 1 such chimera per million total reads were designated as positive 
for HPV viral integration. Normalized HPV E6, E6*, and E7 expression levels were also obtained as above.
Engineering E6 and E6* overexpressing cell lines. Cervical cancer cell lines were obtained from the Amer-
ican Type Culture collection (ATCC) and maintained in IMDM media (Invitrogen) with 10% heat-inac-
tivated FBS and incubated at 37°C in 5% CO2. Mycoplasma testing was performed periodically to verify 
no infection. Last date of  mycoplasma testing for cell lines used in this study was July 17, 2019, for SiHa 
and January 22, 2020, for CaSki and SW756. Experiments were performed on cell lines under passage 
30. CaSki, SiHa, and SW756 were used to evaluate endogenous expression of  HPV E6, E6*, and E7 
transcripts and determine cell sensitivity to radiation treatment by alamarBlue (Thermo Fisher Scientific). 
SiHa had the lowest transcript expression for all HPV transcripts evaluated and was selected to engineer 
cell lines for the overexpression of  HPV 16 E6* and E6. The mammalian expression vector pCMV-6 was 
used as the vector for exogenous HPV transcript expression. Origene VC101902 HPV 16 E6 open reading 
frame (ORF) was used as the codon optimized sequence for HPV 16 E6 minigene (Integrated DNA Tech-
nologies) and customized for HPV 16 E6* with an early stop codon inserted at cDNA position 151 (G > 
T) (Origene); sequences are provided in Supplementary File 1. HPV 16 E6 and E6* ORFs were restriction 
enzyme digested with 10 U/μL SgfI and 10 U/μL MluI, ligated into pCMV-6 vectors using T4 DNA ligase, 
and transformed into 5-α competent E. coli (New England Biosciences [NEB]) overnight and then selected 
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using 25 μg/mL kanamycin LB agar plates. Midiprep of  plasmids was performed using ZymoPure II Plas-
mid Midiprep Kit (ZymoPure) according to manufacturer’s protocol. Purified vectors were transfected into 
SiHa cells using Lipofectamine 3000 (Thermo Fisher Scientific). Transformed cells were G418 selected, 
and resulting cell pools were validated using qPCR for vector E6* and E6 sequence expression.
Western blot. Cells were lysed with Cell Lysis Buffer (Cell Signaling Technology), proteinase/phospha-
tase inhibitors and PMSF on ice for 30 minutes and then sonicated using the Bioruptor UCD-200 (Diageno-
de) on high for 5 minutes. NuPAGE LDS Sample Buffer (4×) (Invitrogen) and SDS buffer (2×) were added, 
samples were boiled at 95°C for 10 minutes and gel electrophoresed on 4-20% gradient gels (Mini-Protean 
TGX, Bio-Rad), transferred to PVDF blot, and blocked with 5% TBST milk. Blots were incubated with 
primary antibodies at 4°C overnight; anti-p21 (1:1000, Cell Signaling Technology [CST], 2947). HRP-con-
jugated secondary antibodies were incubated 1 hour at room temperature; anti-rabbit (1:4000, sc-2357), 
P53-HRP (1:1000, sc-126), and actin-HRP (1:5000 sc-47778) (Santa Cruz Biotechnology Inc.) were used 
with ECL chemiluminescent reagent (GE Healthcare Life Sciences). Blots were visualized and quantified 
using the Bio-Rad ChemiDoc MP imaging system and Image Lab software (Bio-Rad).
qPCR. Total RNA was isolated using the Trizol reagent according to manufacturer’s protocol (Milli-
poreSigma). Altogether, 1 μg of  total RNA was used to synthesize cDNA using High Capacity RNA-to-
cDNA (4387406, Thermo Fisher Scientific) kit per manufacturer’s protocol. Primers for HPV 16 and -18 
native and vector sequences were synthesized by Integrated DNA Technologies, from reference sequences 
(8, 43–45) or as de novo sequences (Supplemental Table 1). Taqman probes were used for the p53 target 
genes: CDKN1A, NOXA, PUMA, BAX, GADD45A, and MDM2 (Thermo Fisher Scientific). Probes for the 
DREAM target genes — BIRC5, CDC25c, KIF23, MYBL2, and PLK4 — were obtained from Thermo Fisher 
Scientific. GAPDH and ACTB were used as reference genes. The qPCR was run at 50°C for 2 minutes, 95°C 
for 10 minutes, and 60°C for 1 minute using the 7900HT Fast Real-Time PCR System (Applied Biosys-
tems). The specificity of  the reaction was verified by melt curve analysis. Data processing was performed 
using SDS 2.4 software (Applied Biosystems), and the relative quantitation of  each mRNA was performed 
using the comparative Ct method as described earlier (46).
SA-β-gal assay. Cells were plated and grown in culture for 7 days, harvested, and stained using the Senes-
cence β-Galactosidase Staining Kit (9860, Cell Signaling Technology) per manufacturers protocol. SA-β-gal+ 
cells were quantified as number of cells per image frame with bright-field microscopy, in nonoverlapping regions.
Proliferation, cell viability, and clonogenic survival. To assess cellular proliferation, cells were plated at a density 
of 0.4 × 106 cells per well and counted 3, 7, 9, and 12 days after plating on Vi-CELL cell counter (Beckman 
Coulter). For both cell viability and clonogenic survival, cells were treated with vehicle (0.01% DMSO) or 0.5 
μM carboplatin 1 hour prior to radiation treatment (2 and 4 Gy). Cell viability was assessed 5 days after treat-
ment using alamarBlue (DAL1025) (Thermo Fisher Scientific) per manufacturers protocol; viability was nor-
malized to untreated samples. For colony formation assay, cells were treated as described, and 48 hours after 
treatment, cells were detached with 0.05% Trypsin and replated at 500 cells/well in a 6-well dish. Cells grew for 
10–12 days, until untreated control wells reached colonies of > 50 cells. Plating efficiency (PE) was calculated 
as (number of colonies in control)/(500 cells seeded), and surviving fraction (SF) was calculated as (number of  
colonies in treated wells)/PE × (500 cells seeded). Cell lines were normalized to their own untreated control 
wells. For p21 knockdown colony formation assay, subconfluent (60%–70%) cells were transfected with 100 
nM of p21 siRNA or control siRNA (Santa Cruz Biotechnology) using Lipofectamine RNAiMAX reagent 
(Invitrogen) in opti-MEM per manufacturer’s protocol. After 48 hours of siRNA transfection, transfected cells 
were irradiated and then processed as described.
Immunofluorescence. SiHa, E6, and E6* cells were seeded on chamber slides (Nunc Lab-Tek) and treated 
with single-fraction 2 Gy RT. Slides were fixed with 4% paraformaldehyde at 10 minutes, 2 hours, 6 hours, 
12 hours, and 24 hours after irradiation. Cells were permeabilized and processed for immunofluorescence 
according to standard protocol. Slides were incubated with primary antibody 1:300 anti–phospho-Histone 
H2AX (Ser139, 20E3, Cell Signaling Technology) at 4°C overnight. Secondary antibody 1:500 Alexa Fluor 
488 goat anti–rabbit IgG (Invitrogen, A11008) incubated 2 hours at room temperature. Slides were mount-
ed using ProLong Gold Antifade Reagent with DAPI (Thermo Fisher Scientific). Slides were imaged with 
the Axio (Carl Zeiss) microscope.
Flow cytometry. Cell cycle and apoptosis were assayed using flow cytometry. For the following assays, 
cells were plated; the next day, they were treated with 0.5 μM carboplatin plus 4 Gy radiation. Cells were 
harvested at 24 and 48 hours following treatment. For cell cycle analysis, cells were washed and then 
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stained with propidium iodide. For apoptosis, cells were washed then stained with annexin V and propidi-
um iodide. Flow cytometry analysis was performed on MacQuant Analyzer and quantified on FlowJo. For 
each sample, 5000 events were collected.
Statistics. Tumor recurrence and OS were the primary endpoints of  the study. Survival outcomes were 
measured from the completion of  treatment. Recurrence was defined as new or progressive disease both 
locally within the pelvis and distantly outside the RT field. The Kaplan-Meier method and log rank test 
were used to determine differences in PFS and OS. R version 3.5.2 and the packages survminer and surviv-
al were used for the analysis. Wilcoxon’s signed-rank test was used to compare patient age between HPV 
cohorts. The χ2 and Fisher exact tests were used for all other patient categorical variables. The Wilcoxon’s 
signed-rank test and 2-tailed Student’s t tests were used for in vitro experiments. One-way ANOVA was 
used when comparing more than 2 groups. P less than 0.05 was set as the threshold for significance for all 
study outcomes.
Study approval. The study population included 88 patients prospectively enrolled into a tumor-banking 
protocol (January 2008 through July 2011). This study was approved by Washington University in St. 
Louis IRB, and all patients provided written informed consent for sequencing (approval no. 201105374). 
RNAseq data can be accessed at Gene Expression Omnibus (GEO) with accession no. GSE151666.
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